Selective Targeting of RET Fusions in Lung Cancer

Selective Targeting of RET Fusions in Lung Cancer

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Jessica J. Lin

Honoraria: Pfizer, OncLive

Consulting or Advisory Role: C4 Therapeutics, Genentech, Nuvalent Inc, Blueprint Medicines, Turning Point Therapeutics, Bayer, Mirati Therapeutics, Novartis, Elevation Oncology

Research Funding: Hengrui Therapeutics (Inst), Turning Point Therapeutics (Inst), Novartis (Inst), Neon Therapeutics (Inst), Relay Therapeutics (Inst), Elevation Oncology (Inst), Bayer (Inst), Roche (Inst), Linnaeus Therapeutics (Inst), Nuvalent Inc (Inst)

Travel, Accommodations, Expenses: Pfizer

Justin F. Gainor

This author is a member of the Journal of Clinical Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript.

Employment: Ironwood Pharmaceuticals

Stock and Other Ownership Interests: Ironwood Pharmaceuticals

Honoraria: Merck, Novartis, Pfizer, Takeda, BeiGene

Consulting or Advisory Role: Genentech, Bristol Myers Squibb, Takeda, Amgen, Merck, Jounce Therapeutics, Blueprint Medicines, Gilead Sciences, Lilly, Moderna Therapeutics, Karyopharm Therapeutics, ITeos Therapeutics, Pfizer, Mirati Therapeutics, Nuvalent Inc, EMD Serono, Silverback Therapeutics, Novartis, BeiGene

Research Funding: Merck (Inst), Novartis (Inst), Genentech, Bristol Myers Squibb (Inst), Adaptimmune (Inst), AstraZeneca (Inst), Jounce Therapeutics (Inst), Blueprint Medicines (Inst), Moderna Therapeutics (Inst), Tesaro (Inst), Alexo Therapeutics (Inst)

Open Payments Link: https://openpaymentsdata.cms.gov/physician/775917

No other potential conflicts of interest were reported.

留言 (0)

沒有登入
gif